


Accepted Manuscript

Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial

Melissa J. Chen, Jennifer K. Hsia, Mitchell D. Creinin



PII: S0010-7824(18)30071-4
DOI: doi:[10.1016/j.contraception.2018.02.009](https://doi.org/10.1016/j.contraception.2018.02.009)
Reference: CON 9050

To appear in:

Received date: 19 December 2017
Revised date: 15 February 2018
Accepted date: 19 February 2018

Please cite this article as: Melissa J. Chen, Jennifer K. Hsia, Mitchell D. Creinin , Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Con(2018), doi:[10.1016/j.contraception.2018.02.009](https://doi.org/10.1016/j.contraception.2018.02.009)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial

Melissa J. Chen, MD, MPH;* Jennifer K. Hsia, MD, MPH;† Mitchell D. Creinin, MD

Department of Obstetrics and Gynecology, University of California, Davis,

4860 Y Street, Suite 2500, Sacramento, CA 95817

* Corresponding Author: Melissa J. Chen, MD, MPH
4860 Y. Street Suite 2500
Sacramento, CA 95817
Phone: 916-734-5673; Email: mejchen@ucdavis.edu

† Dr. Hsia's current affiliation is the Palo Alto Medical Foundation, Mountain View, CA

Abstract word count: 261

Implications word count: 33

Manuscript word count: 1582

Figures: 2; Tables: 3

Clinical Trials#: NCT02852265

Funding: This work was supported by an investigator-initiated grant from Merck & Co.

Disclosures: MDC receives speaking honoraria from Allergan and Gedeon Richter, serves on an Advisory Board for Merck & Co. and is a consultant for Danco, Estetra, Gedeon Richter, and Medicines360. The University of California, Davis Department of Obstetrics and Gynecology receives research funding for contraceptive clinical trials from Contramed, Estetra, Medicines360, Merck & Co., NIH/NICHD, and the Society of Family Planning. MJC and JKH report no other disclosures.

Download English Version:

<https://daneshyari.com/en/article/8777422>

Download Persian Version:

<https://daneshyari.com/article/8777422>

[Daneshyari.com](https://daneshyari.com)